What did @chlo_mckernan actually say?
Honestly? Not much about GLP-1 drugs at all. The transcript from this video, which has racked up 222K views under hashtags like #wegovy and #mounjaro, contains zero medical claims. The creator says: "Don't tilt your crowns, it's not for pressure, not for pain, not for people who couldn't handle your shiny." That's motivational language, not medication guidance.
The caption asks "Anyone else doing the switch from mounjaro to wegovy?" which implies the creator is transitioning between tirzepatide (Mounjaro) and semaglutide (Wegovy). But the spoken content doesn't explain why, describe any protocol, or make clinical comparisons. The medical conversation, if there was one, happened in the comments or a follow-up video, not here.
Does the science back this up?
There's nothing to fact-check in the transcript itself, so let's address the implied question the caption raises: is switching from Mounjaro to Wegovy something the evidence supports?
That's genuinely complicated. Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 receptor agonist. Semaglutide (Wegovy/Ozempic) is a GLP-1 receptor agonist only. In the SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine), tirzepatide at 15mg produced mean weight loss of around 20.9% body weight. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4mg producing about 14.9% mean weight loss. Those aren't head-to-head numbers, but the gap is real and has been replicated.
Why would someone switch from the drug showing greater average weight loss to one showing less? Insurance coverage, cost, tolerability, and supply issues are all legitimate reasons. The science doesn't say switching is wrong, it just says the two drugs work differently.
What did they get wrong (or right)?
There's nothing medically wrong in the transcript because there's nothing medical in it. The motivational framing, "don't tilt your crowns," reads as community encouragement for people navigating GLP-1 treatment, which is common in the #glp1community space.
What's worth flagging is what's missing. A video with 222K views and a caption explicitly about switching GLP-1 medications carries real informational weight whether the creator intends it or not. People in this community are making real medication decisions, and a caption framing a brand switch as casual or self-directed, without any mention of clinician involvement, is a gap. Switching between these drugs isn't like switching shampoos. Tirzepatide and semaglutide have different receptor profiles, different titration schedules, and different tolerability patterns. A physician or qualified prescriber needs to be part of that conversation.
The creator didn't say anything wrong. But the implied framing of the switch as a personal community experience, rather than a clinician-directed change, is where this kind of content can quietly mislead.
What should you actually know?
If you're considering switching from tirzepatide to semaglutide, or vice versa, here's what the evidence actually says.
- These are not interchangeable drugs. Tirzepatide acts on both GIP and GLP-1 receptors. Semaglutide acts on GLP-1 receptors only. They are not equivalent in mechanism or average outcome data.
- Compounded versions of either drug are not the same as brand-name versions. Formulation, excipients, and dosing accuracy differ. This is not a regulatory technicality, it's a safety issue.
- Switching requires a washout and titration plan. You don't just stop one and start the other at your previous dose. Gastrointestinal side effects can be severe if titration is skipped.
- Insurance and formulary issues are the most common real-world reason people switch, not clinical superiority of one drug over another. If cost or access is driving your decision, talk to your prescriber about prior authorization options before switching.
- The #glp1community on TikTok provides genuine peer support. It also contains a lot of anecdotal dosing advice that has not been reviewed by anyone with a medical license. Use it for community, not clinical guidance.
The bottom line
This video is essentially a caption attached to motivational audio. The creator isn't making medical claims, so there's nothing to debunk. But the framing of a significant medication switch as a relatable community moment, without any mention of prescriber involvement, is worth naming. If you're in the GLP-1 community and considering a switch, the right first call is to your prescriber, not your For You page.